SPONSOR
UCB Biopharma SRL
Total Trials
7
Recruiting
7
Phases
Phase 1, Phase 3, Phase 4
Conditions studied: Healthy Study ParticipantsModerate to Severe Plaque PsoriasisPsoriatic ArthritisStereotypical Prolonged SeizuresAxial SpondyloarthritisHidradenitis SuppurativaMyasthenia GravisSystemic Lupus ErythematosusHealthy Participants
NCT06970301 Phase 1
Recruiting
A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants
Healthy Study Participants
NCT06506916 Phase 3
Recruiting
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
Moderate to Severe Plaque Psoriasis
NCT05077904 Phase 3
Recruiting
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Stereotypical Prolonged Seizures
NCT06888193 Phase 1
Recruiting
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Moderate to Severe Plaque Psoriasis
NCT07246564 Phase 4
Recruiting
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Myasthenia Gravis
NCT06617325 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
NCT07286682 Phase 1
Recruiting
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants
Healthy Participants
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology